. Detection of clonal heterogeneity for 49 acute myeloid leukemia (AML) patients; the results from representative flow cytometric analyses of phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) activation. For each patient clonal heterogeneity was detected by analysis
. A correlation visualization with distance matrix displays the pairwise correlation between the 39 patients. Blue and green colors highlight the negative and positive correlation between samples. The genes found differently expressed were thereafter used to identify gene ontology terms (using the David Database for Gene Ontology) that were overrepresented among the genes differently expressed。 Table S1 . A comparison of patients with and without dual AML cell populations; studies of molecular genetics, differentiation and pathway activation profiles. The two subsets do not differ with regard to frequencies of mutations, expression of differentiation Markers or level of PI3K-Akt-mTOR Activation. 
Additional Analysis of AML-Associated Mutations Classification of Mutations and

Molecular and Morphological Signs of Differentiation Expression of differentiation markers.
According to the WHO classification a minor subset of acute leukemia patients show expression of both myeloid and lymphoid markers by their leukemic cells, either as expression of both myeloid and lymphoid markers by the same cells or as separate myeloid and lymphoid subpopulations 2 . However, patients with and without dual populations in the PI3K-Akt-mTOR pathway activation analysis did not differ with regard to the expression of T cell (CD2, CD3, CD4, CD8) of B cell markers (CD19, CD20), and we could not detect any differences between the two patient subsets with regard to myeloid marker (DCD11b, CD11c, CD13, CD14, CD15, CD33), stem cell markers (CD34, CD117) or HLA-DR expression. Morphological signs of differentiation. The FAB classification did not differ between the two subsets.
Activation Profile of The PI3K-AKT-mTor Pathway The constitutive activation of mediators within the PI3K-Akt-mTOR pathway varies between patients 3 . Hence, we performed a clustering analysis to identify patients with similar pathway activation profiles, but the profiles did not differ between patients with and without detectable clonal heterogeneity. Table S2 . The GO-term showing significant differences when comparing AML cell populations for patients with and without clonal heterogeneity; the comparison being based on analysis of Molecular function. The genes included in the analysis were identified by the comparison of 12 AML patient samples with and 27 samples without evidence for clonal heterogeneity when analyzing the PI3K-AktmTOR pathway. Two GO-terms were then identified based; G-protein coupled receptor activity (GO:0004930; p-value 0.00002; 36 genes included) and Olfactory receptor activity (GO:0004984; p-value 0.000024; 26 genes included). Several genes were included in both these terms; genes that did not overlap between these two terms are shaded in grey. Increased or decreased gene expression for patients with detectable subpopulations when analyzing constitutive PI3K-Akt-mTOR inhibition is indicated by upward arrows (↑) and downward arrows (↓), respectively. Table S5 . The complete gene list from patients without dual AML cell populations. We compared the global gene expression profiles for 12 AML samples with and 27 samples without dual AML cell populations. A feature subset selection (FSS) analysis was performed for identification of the most discriminative genes between the two groups, and 1209 genes were then identified (i.e., p-value <0.05). 
Gene ID
